Eevia Board has resolved to exercise its current authorization issuing 6,000,000 new warrants (TO2). It is granting these warrants to Lago Kapital Oy, a Finnish investment firm.
 

The Board is planning to undertake private placements of shares (directed equity issues) as earlier announced to compensate for shares that were not subscribed in the last rights issue. The target of the efforts is approximately KEUR 400 of which the TO2 Warrants is a smaller part of. In connection with the warrant issue Orcator Oy, one of Eevia’s shareholders, has agreed to lend a total of 6,000,000 shares to Lago Kapital Oy. Stein Ulve, CEO and a PMDR of Eevia, is an owner of Orcator Oy.

Eevia has a weighty financial reason for the issuance of Warrants TO2, since the Company estimates that it will need more working capital to be able to continue its systematic streamlining, to achieve profitability targets and to meet growing demand. Furthermore, the Company has arranged two rights issues in the last nine months, both of which were subscribed less that the full offering. Issuance of the Warrants TO2 is seen as a cost-efficient alternative to obtain additional capital for the Company in the future.

The subscription period for shares subscribed for based on the Warrants TO2 shall be May 12 – June 9, 2025. Each warrant of series TO2 entitles the holder to subscribe for one (1) share at a subscription price equal to 70 per cent of the volume weighted average price (VWAP) of the Company's share on the Spotlight Stock Market during the subscription period, but not less than 0.11 SEK.

Warrants that have not been exercised on June 11 will lapse automatically. The warrants include conditions on accelerated vesting in case of change of control, e.g., takeover bid, merger, or delisting. The Warrants TO2 shall be issued with a charge of 0,1 Swedish Øre (SEK 0,001) per one (1) Warrant of series TO2.

“The TO2 Warrants, and a direct equity issue will help Eevia Health to exploit some significant immediate commercial growth opportunities. These equity transactions will also support ongoing efforts to achieve non-dilutive funding (R&D Loan) of c. KEUR 550 from applications we expect to get decisions on by Mid-May,” says Stein Ulve, CEO of Eevia Health.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.com

Telephone: +358 400 22 5967

Information about Eevia Health Plc

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.